Parkinson’s Disease and Diabetes Mellitus: Synergistic Effects on Pathophysiology and GI Motility

被引：8
作者：
Yan Y. [1 ]
Shimoga D. [1 ]
Sharma A. [1 ]
机构：
[1] Division of Gastroenterology and Hepatology, Department of Medicine, Medical College of Georgia, Augusta University, 1120 15th Street, AD 2226, Augusta, 30912, GA
来源：
Current Gastroenterology Reports | 2023年 / 25卷 / 5期
关键词：
Diabetes; Gastrointestinal; GLP-1 receptor agonists; Gut-brain axis; Nonmotor symptoms; Parkinson’s Disease;
D O I：
10.1007/s11894-023-00868-7
中图分类号：
学科分类号：
摘要：
Purpose of Review: Parkinson’s disease and diabetes affect an increasing proportion of the aging global population. Both conditions extensively affect gastrointestinal (GI) motility with similar and differing clinical symptoms. Nonetheless, GI symptoms in Parkinson’s disease and diabetes pose significant morbidity and impairment of quality of life. Their pathophysiology is poorly understood, and therefore, effective treatment options are lacking. Recent Findings: Parkinson’s disease patients have oropharyngeal dysphagia and constipation. They also have mild or absent upper GI symptoms associated with delayed gastric emptying, which is prevalent in 70% of patients. Delayed gastric emptying in Parkinson’s disease leads to erratic medication absorption and fluctuating motor symptoms. Half of diabetics have upper GI symptoms, which correlate to gastric emptying and changes in brain activity of the insular cortex. The majority of diabetics also have constipation. Diabetics have an increased risk for developing Parkinson’s disease and anti-diabetic medications are associated with risk reduction of developing Parkinson’s disease. Hyperglycemia is associated with advanced glycated end products formation and acceleration of α-synuclein aggregation. GLP-1 receptor agonists have also demonstrated efficacy in improving motor symptoms and cognition in Parkinson’s disease patients with diabetes. Summary: Parkinson’s disease and diabetes are pan-enteric disorders with significant GI symptoms and impairment of gut motility. Both conditions have synergistic pathophysiologies that propagate neurodegenerative changes. Treatment options for GI symptoms in diabetic and Parkinson’s disease patients are lacking. Anti-diabetic treatment improves motor symptoms in Parkinson’s disease, however, its effect on GI symptoms is unclear. © 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
引用
收藏
页码：106 / 113
页数：7
相关论文
共 78 条
[1]  
Dorsey E., Et al., Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030, Neurology, 68, 5, pp. 384-386, (2007)
[2]  
Dorsey E.R., Et al., Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the global burden of Disease Study 2016, Lancet Neurol, 17, 11, pp. 939-953, (2018)
[3]  
Sharma A., Et al., Constipation in Parkinson’s disease: a nuisance or nuanced answer to the pathophysiological puzzle?, Curr Gastroenterol Rep, 20, pp. 1-9, (2018)
[4]  
Horsager J., Et al., Brain-first versus body-first Parkinson’s disease: a multimodal imaging case-control study, Brain, 143, 10, pp. 3077-3088, (2020)
[5]  
Hilton D., Et al., Accumulation of α-synuclein in the bowel of patients in the pre-clinical phase of Parkinson’s disease, Acta Neuropathol, 127, pp. 235-241, (2014)
[6]  
Travagli R.A., Browning K.N., Camilleri M., Parkinson disease and the gut: new insights into pathogenesis and clinical relevance, Nat Reviews Gastroenterol Hepatol, 17, 11, pp. 673-685, (2020)
[7]  
Del Tredici K., Braak H., Spinal cord lesions in sporadic Parkinson’s disease, Acta Neuropathol, 124, pp. 643-664, (2012)
[8]  
Kleine Bardenhorst S., Cereda E., Severgnini M., Et al., Gut microbiota dysbiosis in Parkinson disease: A systematic review and pooled analysis, Eur J Neurol, pp. 1-14, (2023)
[9]  
Nishiwaki H., Et al., Meta-analysis of gut dysbiosis in Parkinson’s disease, Mov Disord, 35, 9, pp. 1626-1635, (2020)
[10]  
Mawe G.M., Et al., 2021 workshop: neurodegenerative Diseases in the gut-brain Axis—Parkinson’s Disease, Gastroenterology, 162, 6, pp. 1574-1582, (2022)
12345678